Abstract 22
The purpose of this study was to develop micron-sized droplet emulsions able to increase the heat 23 deposition of high intensity focused ultrasound (HIFU), aiming to accelerate the tumour ablation in 24 highly perfused organs with reduced side effects. The investigated droplets consisted of a 25 perfluorooctyl bromide (PFOB) core coated with a biocompatible fluorinated surfactant called F-TAC. 26
The novelty of this work relies on the use, for this application, of a high boiling point perfluorocarbon 27 core (142°C), combined with an in-house fluorinated surfactant to formulate the emulsion, yielding 28 quasi-reversible strong interactions between the HIFU beam and the droplets. In order to fine-tune 29 the emulsion size, surfactants with different hydrophobic/hydrophilic ratios were screened. Different 30 concentrations of PFOB droplets were homogeneously embedded in two different MRI compatible 31 tissue mimicking materials (TMM), exhibiting either ultrasound (US) absorbing or non-absorbing 32
properties. For the US absorbing TMM, the speed of sound at each droplet concentration was also 33 assessed. These TMM were sonicated by 1 MHz HIFU with acoustical power of 94 W at two different 34 duty cycles. The temperature elevation was monitored accurately by MRI proton shift resonance 35 frequency in near real-time. The presence of sono-sensitive droplets induced a significant increase of 36 the HIFU thermal effect that persisted under repeated sonication of the same locus. Optimal 37 enhancement was observed at the lowest concentration tested (0.1%) with an additional 38 temperature rise at the focal point of approximately 4 °C per applied kJ of acoustic energy 39 corresponding to one order of magnitude augmentation of the thermal dose. Furthermore, no 40 deformation of the heating pattern pre-or post-focal was observed. 41
Introduction

44
High intensity focused ultrasound (HIFU) is a promising non-invasive and non-ionizing 45 treatment for ablation of solid tumours. 1, 2 It has FDA approval for the treatment of uterine 46 fibrosis 3 , and is in clinical development to treat several solid malignant tumours including 47 liver, prostate, breast, bladder, kidney and soft tissue sarcoma. [4] [5] [6] [7] [8] [9] [10] However, it possesses 48 several shortcomings such as long treatment duration to fully ablate the tumour 1, 11 and, for 49 deep-seated tumours, high ultrasound (US) intensity is required leading to an increase in 50 side effects. In addition, even when US energy is concentrated to the focal point, it can also 51 be deposited along the US beam in front or behind the focus point and cause severe side 52 effects such as skin and bone burning. 8,12-14 Furthermore, given a treatment planning, inter-53 patient variation in the volume and shape of the lesion may be difficult to control and to 54 reproduce. 15 
55
The ablative effects of HIFU are due to the focusing of high energy beams in a small 56 region on the order of the wavelength, i.e. on the millimetre scale. 1 At the focal spot, the HIFU and hence to decrease the occurrence of side effects. The first approach was to use 66 microbubbles (MB) filled with perfluorocarbon (PFC) gas that were originally used for 67 ultrasound contrast enhancement. 11, 17, 18 The MB serve as nuclei for inertial cavitation (IC) 68 and act as enhancers of tissue heating rate as they absorb energy from the sound wave 69 when they oscillate. 16, 19 However, as they are ultra-sensitive to US with a very low IC as a white powder with yields ranging from 31.8% to 84.0% (see Table 1 ). glycerol, the silicon oxide mixture and degassed water (see Table 2 ) were added to a 400 ml 236 tared beaker. And under mechanical stirring the mixture was heated and then agar was 237 added. The solution was heated at above 90°C for one hour. Then the gel was set to cool 238 down under magnetic stirring and any water lost was compensated with degassed water.
239
Then when the mixture reached about 40°C; the emulsion (see Table 2 ), loaded with three 240 drops of methylene blue, was added, homogenised and cool down. The volume fraction of 241 PFOB in TMM was used to describe the MSD concentration (see Table 2 ). 
Optical microscopy
274
The optical microscopy was performed on an Olympus BX60 microscope (Olympus, Rungis,
275
France) with 100x magnification (see Figure 1c ) and no spectral filter. All measurements were performed using a 3T whole body MR system (Prisma Fit, Siemens, shown by the MSD size distribution in Figure 1 .b, the droplets obtained with F 6 TAC 7 438 displayed a very high polydispersity (d90/d10=4.00) 42 which was also confirmed by optical 439 microscopy ( Figure 1.c) . 440 The method of MSD titration was modified from the one published by Astafyeva et al 42 in 441 order to obtain a totally homogenous solution containing both PFOB and water. To do so, we 442 used a ternary system made of a mixture of methanol and diethyl ether, the latter being 443 used to ensure complete solubilisation of PFOB in the solution. 56 The concentration of PFOB 444 in the emulsion was thus estimated to be 11.6 ± 0.9 %, which indicated a loss of about 15% 445 of water during the synthesis process. 
Effect of choice of surfactant on the MSD ultrasound absorption
544
The best potential candidate surfactant according to Table 3 regarding the average diameter   545 (F 8 TAC 7 and F 6 TAC 7 ) were investigated for comparative MSD effect on the HIFU absorption in 546 non-absorbent gel (Table 5, Table 6 showed that after the repetition of HIFU exposure in the non-absorbent gel at 556 the same location, a slight decrease of 5% of thermal deposition per cycle was observed 557 between the first shot and the second shot and 10 % between the first shot and the third 558 shot, this tendency is also illustrated with graphical plots in Figure 5 . In this proof of concept study, we demonstrated significant enhancement of the HIFU 579 absorption in presence of tailored-made sono-sensitive MSD, however, a parametric study 580 was not performed to determine the influence of the acoustic intensity levels and duration 581 of sonication on the enhancement effect. These investigations are required in order to 582 optimize the HIFU pulse sequence to be applied to the respective MSD.
583
Future in vivo studies need to be performed to confirm the thermal enhancement 584 produced by the current MSD. As compared to the present in vitro study, there are some 585 different conditions to be considered. Firstly, the fraction of acoustic power transferred to 586 tissue will change as the absorption properties, stiffness and viscosity will be different from 587 our TMM. Secondly, the droplets will be confined to the blood vessels as we target tumours 588 in highly perfused organs (e.g. kidney or liver). Thirdly, we may be not able to reach, in vivo, 589 the droplet concentration added to the gels, however, significant dose reduction is likely to 590 be achieved. According to Figure 5a, 
923
(non-absorbent gel). The same acoustic parameters were applied after 5 minutes delay at the same location.
924
The ulterior sonications gradually induce less thermal effect. The blue line corresponds to the first sonication, 925 the red line corresponds to the second sonication and the black line to the third sonication.
